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Abstract
Background: The dominantly inherited condition familial adenomatous polyposis (FAP) is caused by
germline mutations in the APC gene. Finding the causative mutations has great implications for the families.
Correlating the genotypes to the phenotypes could help to improve the diagnosis and follow-up of
patients.
Methods: Mutation screening of APC and the clinical characterization of 96 unrelated FAP patients from
the Swedish Polyposis Registry was performed. In addition to generally used mutation screening methods,
analyses of splicing-affecting mutations and investigations of the presence of low-frequency mutation
alleles, indicating mosaics, have been performed, as well as quantitative real-time polymerase chain
reaction to detect lowered expression of APC.
Results: Sixty-one different APC mutations in 81 of the 96 families were identified and 27 of those are
novel. We have previously shown that 6 of the 96 patients carried biallelic MUTYH mutations. The 9
mutation-negative cases all display an attenuated or atypical phenotype. Probands with a genotype (codon
1250–1464) predicting a severe phenotype had a median age at diagnosis of 21.8 (range, 11–49) years
compared with 34.4 (range, 14–57) years among those with mutations outside this region (P < 0.017).
Dense polyposis (> 1000) occurred in 75% of the probands with a severe phenotype compared with 30%
in those with mutations outside this region. The morbidity in colorectal cancer among probands was 25%
at a mean age of 37.5 years and 29% at a mean age of 46.6 years.
Conclusion: Using a variety of mutation-detection techniques, we have achieved a 100% detection
frequency in classical FAP. Probands with APC mutations outside codon 1250–1464, although exhibiting a
less-severe phenotype, are at high risk of having a colorectal cancer at diagnosis indicating that age at
diagnosis is as important as the severity of the disease for colorectal cancer morbidity.
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Background
The dominantly inherited condition familial adenoma-
tous polyposis (FAP) is caused by germline mutations in
the APC gene (5q21-q22; MIM#175100) [1,2]. The classi-
cal FAP phenotype is defined by hundreds to thousands of
adenomatous polyps that develop in the large intestine,
conferring a high risk of colorectal cancer (CRC). A variety
of extra-colonic manifestations exist in FAP. Duodenal
adenomas are common and carcinomas of the duodenum
are a main cause of death in FAP patients. Patients also
have an increased risk of developing extra-intestinal
tumors, for example, desmoids. Recently, a new type of
colorectal adenomatous polyposis has been described,
MUTYH-associated polyposis (MAP) [3] or MUTYH-asso-
ciated CRC (MIM#608456). MAP is caused by biallelic
mutations in the MUTYH  (mutY homologue;
MIM*604933) gene (1p32.1-p34.3) and is inherited in a
recessive manner [4,5].
The majority of germline APC mutations identified in FAP
families cause truncations in this multifunctional protein
[6,7]. The APC truncations most often occur as the result
of nonsense APC  mutations or frameshifts caused by
small deletions/insertions. Large APC deletions are found
in a limited number of FAP cases. By using methods such
as quantitative real-time PCR (polymerase chain reaction)
or MLPA (multiplex ligation-dependent probe amplifica-
tion) rather than conventional mutation-detection tech-
niques, we can achieve higher detection rates of large
deletions [8-12]. The number of reported characterized
APC splice-site mutations is comparatively low [13-17].
Approximately 10–15% of the FAP patients could have a
reduced or absent APC expression [18]. The cause of the
reduced expression is not known but the patients show a
similar phenotype to those with an identified truncating
APC mutation [19-21]. It has been shown that a decrease
of approximately 50% of the expression of an allele can
result in a predisposition to FAP [20]. Germline APC-
mutation mosaicism in FAP patients has been reported
[22-25] but is not generally included in the mutation
screening procedure provided by most labs owing to the
technical difficulties encountered with these analyses.
Different genotype-phenotype correlations in FAP have
been suggested [26-28]. The classic phenotype is primarily
caused by mutations in the central part of the APC gene.
Mutations around codon 1309 cause a severe course of
disease with early onset and profuse polyposis. The
milder, attenuated form of disease (AFAP), characterized
by less than 100 adenomas and later onset of adenomato-
sis and CRC, is often caused by mutations in the far 5' and
3' regions of the APC gene, as well as in the part excluded
by alternative splicing of exon 9 [29].
In the present study patients included in the Swedish
Polyposis Registry were subjected to a thorough clinical
characterization and mutational screening of the APC
gene including screening for large deletions and detection
of low-frequency alleles caused by germline mosaicism.
Sixty-one mutations, including 27 not described previ-
ously, are reported. Among the characterized mutations
are elusive changes such as a case of mosaicism, splicing
defects, and a mutation in APC exon 1 which is the most
5'  APC  mutation hitherto reported. The detection of
reduced APC expression in one family is also described. A
combination of mutation screening techniques was used
to achieve as high a mutation-detection frequency as pos-
sible.
Methods
Patients
Between 1957 and 31 December 2004 the Swedish Poly-
posis Registry included data on 196 families with verified
FAP (defined as more than 100 colorectal adenomas or if
less with a family history of FAP). Sixty-one of these fam-
ilies are now extinct but 135 families with at least one liv-
ing disease-affected member remain. Presently, 315
disease-affected living patients are included in the registry.
The geographical catchment area comprises the whole of
Sweden. Details of how patients have been eligible for
accession into the registry are given in [30]. In this study
we have analyzed 96 families included in the registry for
mutations in the APC gene. Twenty-four of the remaining
39 families have been analyzed for APC gene mutations at
other genetic laboratories and 15 families remain to be
tested. We have previously reported six of these patients
who carried bi-allelic MUTYH mutations [31]. Probands
were defined as those diagnosed on the basis of the occur-
rence of symptoms and irrespective of other cases in the
family and call-up patients, as those identified as subjects
at risk on the basis of studies of pedigrees and found to
have FAP. De novo mutations were defined in those indi-
viduals where none of the parents carried the mutation or
where the parents had a negative colonoscopy after the
age of 50 or died of a non-FAP related cause after the age
of 75. All patients have given their consent and the local
ethics committees have approved the study. The clinical
features of index patients of each of the families analyzed
are listed in Additional file 1 and Table 1.
Patient C896, with only five adenomas, was included
because of a family history of FAP. Patient C107 under-
went her first colonoscopy due to intestinal bleeding at
age 47. At diagnosis, 10–20 small (less than 10 mm) pol-
yps were found in most colorectal parts. Tubular and tub-
ulovillous adenomas were removed yearly. At age 50,
carcinoma (Dukes A) was diagnosed 4 cm from valvula
Bauhini in conjunction with several new adenomas. AtBMC Medicine 2008, 6:10 http://www.biomedcentral.com/1741-7015/6/10
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that time the patient underwent total colectomy with ile-
orectal anastomosis (IRA).
DNA, RNA and cDNA preparation
Genomic DNA was isolated from samples of venous
blood, anti-coagulated in ethylenediaminetetraacetic acid
(EDTA). DNA purification was performed using the Pure-
geneR DNA Isolation Kit (Gentra Systems, Minneapolis,
MN) according to the manufacturer's recommendations.
DNA was extracted from paraffin-embedded tissue as
described previously [32]. Histopaque (Sigma, St Louis,
MO) or Lymphoprep (Axis-Shield PoC AS, Oslo, Norway)
was used for purification of the lymphocytes, and total
RNA was extracted using RNA-Stat 60 (Tel-Test, Friends-
wood, TX). cDNA was synthesized as described previously
[33].
Molecular genetic analysis of the APC gene
Mutational screening of APC was initialized with DNA
(exon 15) and, whenever possible, RNA-based (exons 1–
14) PTT (protein truncation test). SSCP/HD (single-strand
conformational polymorphism/heteroduplex), D-HPLC
(denaturing high-performance liquid chromatography)
on the Wave instrument (Transgenomic, Omaha, NE),
and/or DNA sequencing was applied for screening of
exons 1–14. DNA sequencing of exon 15 was performed
when no mutation had been detected in the initial search.
Patients C107, C257 and C505 with no documented
inheritance of FAP and where no mutation in the entire
APC or MUTYH genes could be detected, were subjected
to analyses for mosaic mutations using SSCP/HD. PCR,
RT-PCR (reverse transcriptase PCR), SSCP/HD, and PTT
were carried out as described previously [33] with the fol-
lowing changes: the Criterion Tris-HCl 8–16% gels and
Criterion Gel Electrophoresis System (BioRad Laborato-
ries, Hercules, CA) were used for the PTT. Primers used for
PCR amplification of genomic DNA for subsequent DNA
sequencing or PTT are available from the authors upon
request.  Taq  DNA polymerase (Amersham Biosciences
Corp, Piscataway, NJ or Promega Corporation, Madison,
WI) was used for PCR amplification prior to DNA
sequencing. DNA sequencing was performed on PCR
products purified with ExoSAP-IT (USB, Cleveland, OH).
Sequence reactions were carried out using ABI Prism Big
Dye Terminator Cycle Sequencing kit (Applied Biosys-
tems, Foster City, CA) and analyzed on the ABI Prism
3100 Genetic Analyzer (Applied Biosystems) according to
the manufacturer's protocol. MLPA [34] was used to
detect deletions/duplications of one or more exons and
was carried out as described by Meuller et al [10]. All
MLPA analyses were carried out in duplicates and normal-
ized against two different control individuals. All muta-
tions described in this study were verified in a second
independent analysis using, as far as possible, an alterna-
tive mutation-detection technique.
Analyses of APC expression
The level of APC mRNA expression in peripheral blood
cells was investigated by TaqMan quantitative real-time
PCR (RT-PCR) analysis in 29 patients from 18 families.
RT-PCR was carried out using ABI Prism 7900HT
Sequence Detection System (Applied Biosystems) at the
Gothenburg Genomics Core Facility. Primers and probe
for the APC gene as well as for GAPD, which was used as
internal control, were obtained from [35]. Amplification
reactions were performed for the two genes separately in a
volume of 10 μl containing 1 μl template cDNA diluted
1:10, 1 × FAM-labeled Assay-on-Demand Gene Expres-
sion Assay Mix, and 1 × TaqMan Universal PCR Master
Mix (Applied Biosystems). Thermal cycling was per-
formed according to the standard protocol. Triple samples
of each patient were analyzed and no-template controls
were included in the experiments. As the standard curve
method for quantification of RT-PCR products would be
used, a series of dilutions of calibrator cDNA were also
included. The fluorescence intensities detected during the
PCR process were analyzed and converted into threshold
cycle values (Ct-values) using the SDS 2.0 software
(Applied Biosystems). Using the obtained standard curve
for each gene, the concentration of APC and GAPD in each
Table 1: Patients without any detected mutation in APC or MUTYH
Patient Age Inheritance Sex Number of polyps CRC DL FGP
C139 36 dom F 50 N Y Y
C146 74 NA M 40–50 Y N N
C257 52 NI F 20 Y N N
C369 44 dom F 120 N N Y
C380 34 dom F 15 Y - -
C505 45 NI F 20 Y N N
C896 41 dom F 5 Y N N
3210 40 dom F 20 N - -
3752 36 rec M 10 N N N
Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, 
number of polyps at diagnosis; rec, recessiveBMC Medicine 2008, 6:10 http://www.biomedcentral.com/1741-7015/6/10
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sample was calculated from the mean Ct value of each trip-
licate. The APC value was then normalized against the
housekeeping gene GAPD to obtain a relative measure-
ment of the level of APC expression in the blood of the
patient. The Dunnett t-test was used to calculate statistical
significance. To verify the expression data, cDNA from the
positive individuals was sequenced over an informative
heterozygous cSNP position (c.5465A > T). The level of
expression of each allele could then be estimated.
Statistics
Student's t-test was used to analyze continuous data, and
Fisher's exact test was used to analyze categorical data. Dif-
ferences were considered statistically significant at a level
of P < 0.05.
Results
Sixty-one different APC mutations, 27 novel and 34 recur-
rent, were detected among 81 of the 96 Swedish families
studied as shown in Additional files 1 and 2. A mutation
spectrum displaying the distribution between novel and
previously reported mutations is shown in Figure 1. The
frequency of APC de novo mutation cases among the fam-
ilies was 16%. In three of the families parents were tested
negative for the mutation and in the remaining seven fam-
ilies we where unable to obtain samples to test parents.
Thirty-two of the 81 patients with APC mutations were
probands. Probands with mutations in the region from
codon 1250 to 1464 of the APC gene which predicts a
severe phenotype [36] had a median age at diagnosis of
21.8 (range, 11–49) years compared with 34.4 (range,
14–57) years among those with mutations outside this
Mutation spectrum of the APC gene Figure 1
Mutation spectrum of the APC gene. (A) The spectrum of APC mutations identified among families from the Swedish 
Polyposis Registry showing the distribution between previously reported and novel mutations in our patients. (B) A schematic 
representation of the APC coding region, shown in the same scale as in (A). The arrow with an asterisk indicates codon 24 and 
the second arrow points at codon 184. (C) Distribution of six large deletions found in seven unrelated patients of the Swedish 
Polyposis Registry. Novel deletions are marked with an asterisk. Patient numbers are shown to the left. Scale as in (A).BMC Medicine 2008, 6:10 http://www.biomedcentral.com/1741-7015/6/10
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region (P  < 0.017). Available data on colorectal polyp
number shows that, in spite of higher age at diagnosis,
dense polyposis (> 1000) only occurred in 30% of the
probands compared with 75% in those with mutations
between codon 1250 and 1464. In the former group 29%
(7 out of 24) had CRC at diagnosis compared with 25%
(2 out of 8) in the latter group. The mean age at CRC was
46.6 (range 28–57) and 37.5 (range 26–49) years, respec-
tively. The total morbidity in CRC among probands was
34% (11 out of 32). Of all probands diagnosed after 1996,
four out of nine (44%) had cancer at diagnosis. The
median age in this group was 47.5 (range 45–51) years
and none had, despite high age at diagnosis of CRC, dense
colorectal polyposis at diagnosis indicating a less-severe
phenotype. A compilation of clinical status of all patients
analyzed in this study is shown in Additional file 1.
Large deletions of the APC gene
Seven of the identified APC mutations were large dele-
tions, ranging from a deletion of 86 bp in exon 15 to a
deletion of the whole APC gene (Figure 1C). Three of
these deletions have not, to the best of the authors' knowl-
edge, been described earlier. The deletion encompassing
APC  exon 4 in patient 3765, c.423-
1662_531+1825del3595, was detected by RNA-based PTT
with subsequent cDNA sequencing and verified by long-
range PCR on genomic DNA. We could not detect this
deletion with MLPA even though a probe for exon 4 is
included in the MLPA kit (see the discussion). Detection
of the large deletion in patient C591, encompassing APC
exons 13 through the 5' part of exon 15, was carried out
with MLPA. The deletion in patient 2136 was identified by
PTT and subsequent DNA sequencing.
A case of APC mosaicism
Three patients (C107, C257, and C505), negative for
mutations in APC, were reported as de novo cases with no
known family history of FAP. These patients where all
screened for APC mutations present as low-frequency alle-
les using SSCP/HD. We did not detect any signs of low-fre-
quency mutations in patients C257 and C505. However,
in patient C107, aberrant bands, possibly originating
from formation of heteroduplexes, was detected by SSCP/
HD in a very low fraction of her blood lymphocytes. The
c.2700_2701delTC mutation, which results in frame shift
at codon 900, was found by sequencing of the aberrant
bands excised from the SSCP/HD gel (Figure 2A). The
mutation was detected in approximately one-third of the
analyzed tumor-derived cells extracted from paraffin-
embedded tissue by DNA sequencing (Figure 2B). The
mutation was not detectable at all in the sequence deter-
mination of DNA extracted from blood lymphocytes from
the patient (Figure 2C).
Mutation at the far 5'end
DNA sequencing of APC exon 1 in patient C157 revealed
the c.70C > T substitution which introduces a nonsense
mutation in codon 24 (Figure 1). The mutation was also
detectable by SSCP/HD analysis but was not detectable by
PTT due to its localization close to the 5' end of the PTT
fragment. However, indication for a mutation was
observed as lowered intensity of the full-length fragment.
Splice-site affecting mutations
When investigating patient C496 with RNA-based PTT, an
aberrant APC polypeptide pattern was detected (data not
shown). Sequencing of the corresponding cDNA fragment
identified a change in the beginning of exon 8 (Figure 3).
Genomic sequencing of exon 8 and the flanking intron
sequences lead to the discovery of the c.835-7T > G muta-
tion (Figure 3A). The base substitution introduces a new
AG splice-acceptor site eight bases upstream of exon 8.
Owing to the use of this new splice site the last six bases
of intron 7 are included in the transcript, resulting in pre-
mature truncation (Figure 3B). The entire APC  coding
region of the patient was sequenced and no other patho-
genic variants were detected. A search for deletion or
duplication of one or more exon in the APC gene by MLPA
was also carried out with negative result.
The APC mutation in patient C633 was also detected by
RNA-based PTT, followed by cDNA sequencing and
genomic sequencing of APC exon 7 (Figure 4). The c.834G
> C mutation changes the normal splice donor site of
exon 7. This substitution reduces the score for usage of the
wild-type splice donor site according to [37]. An alterna-
tive cryptic splice donor site 11 bp upstream in exon 7 is
used in the mutant allele, leading to the aberrant splicing
of exon 7. The resulting APC mRNA carries a frameshift,
caused by the 11-bp deletion in the 3' end of exon 7,
which leads to the premature truncation of the protein in
exon 8. A third novel mutation affecting splicing of the
APC  gene was detected by PTT analysis and genomic
sequencing of patient C232. A complex deletion/insertion
was detected that affects the splicing of APC intron 3, APC
c.423-6del8ins13 (in detail APC c. 423 -
6delAAATAGGTinsGAAGCAAGATCAG).
A family with reduced APC expression
Lowered APC expression was observed in samples from
two affected individuals from family 1 in the Swedish
Polyposis Registry (index case, C152). The level of APC
mRNA expression in peripheral blood cells from these
two individuals where investigated by TaqMan quantita-
tive RT-PCR analysis. In total, 29 patients including all 9
mutation-negative cases were analyzed. APC- and
MUTYH-mutation positive patients as well as healthy
individuals where included as controls. Reduced APC
expression was only observed in two samples fromBMC Medicine 2008, 6:10 http://www.biomedcentral.com/1741-7015/6/10
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Detection of the mosaic c.2700_2701delTC mutation in patient C107 Figure 2
Detection of the mosaic c.2700_2701delTC mutation in patient C107. Nucleotide 2700 is indicated with an arrow. 
(A) The aberrant bands indicated by the bracket were excised from the SSCP/HD gel. The resulting DNA sequence is shown 
to the right. (B) DNA sequence from DNA extracted from tumor-derived cells from the patient. (C) The DNA sequence 
from DNA isolated from the patient's blood lymphocytes.BMC Medicine 2008, 6:10 http://www.biomedcentral.com/1741-7015/6/10
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Characterization of the mutation in patient C496 Figure 3
Characterization of the mutation in patient C496. (A) Genomic sequence of the patient showing the c.835-7T > G 
mutation. The new splice site generated by the T > G substitution is indicated with a dashed line, the wildtype acceptor-splice 
site is underlined, and the regular start of exon 8 is indicated with an arrow. (B) cDNA sequence covering the exon 7–8 
boundary, indicated with a dashed line. Shown below the sequence diagram is the interpretation of the sequence reflecting the 
two mRNA species present in the sample. The insertion of 6 bp owing to the introduction of a new splice site in the mutant 
allele is shown as a shaded area. Predicted amino-acid sequence of translation products are shown above and below the 
respective cDNA sequence.BMC Medicine 2008, 6:10 http://www.biomedcentral.com/1741-7015/6/10
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affected individuals and both of those where from family
1 (Figure 5A). The APC-mutation positive samples used as
controls did not show reduced expression of APC. To ver-
ify the expression data, cDNA from the individuals was
sequenced over an informative heterozygous cSNP posi-
tion (c.5465A > T). By sequencing cDNA and monitoring
the level of expression of each allele as shown by the
sequence diagram (Figure 5B), the level of the T-allele was
found to be lowered in the two FAP-affected members of
the family, compared with control individuals who had
displayed normal APC expression in the quantitative RT-
PCR experiment (Figure 5A). Linkage to the APC locus on
chromosome 5 has also been investigated in this family.
Positive linkage in two different branches of the family
was determined. Individuals who have shown positive
linkage to APC are indicated in Figure 6, which shows a
pedigree presenting only a part of the complete pedigree
of the large family 1. In total, this family includes 150
individuals of whom 57 are affected by the disease.
Discussion
The APC mutations identified in the Swedish patients are
scattered along the APC gene (Figure 1). The most 5' situ-
ated pathogenic germ line APC mutation identified in this
study, in codon 24 of exon 1 (c.70C > T), was detected
when analyzing patient C157. This may be the most 5'
location of any mutation detected in the coding region of
APC (Figure 1[38]). Codon 24 is within the oligomeriza-
Characterization of mutation in patient C633 Figure 4
Characterization of mutation in patient C633. Diagram of genomic DNA sequence at the exon/intron 7 boundary. The 
line arrow indicates the c.834G > C mutation and the wildtype 5' donor splice site of intron 7 is underlined in the sequence 
diagram. The wildtype cDNA and the resulting amino acid sequence from the corresponding transcript are shown above the 
diagram. The G that is substituted in one allele in the patient is indicated in bold. The cryptic splice site used as a result of the 
mutation is underlined with a dashed line and the shaded area corresponds to the mRNA sequence deleted in the mutant tran-
script. Beneath the genomic sequence the cDNA sequence derived from the mutant allele is displayed, showing the resulting 
frameshift and premature termination of the translation product.BMC Medicine 2008, 6:10 http://www.biomedcentral.com/1741-7015/6/10
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tion domain at the N-terminus of APC, encoded by amino
acids 6–57 [39]. The most 3' situated mutation identified
in the present study (C159) is a frameshift at codon 1920.
The most frequently found mutation was the well-known
c.3927_3931del AAAGA (amino acid position 1309)
mutation detected in 10 out of the 95 patients. The recur-
rent mutation c.3183_3187delACAAA (amino acid 1061)
was found in four patients. The frequency of de novo muta-
tion cases was 16% which is lower than the estimation of
20–25% reported by Bisgaard et al [40]. The most fre-
quent mutation occurring de novo was c.3927_3931del
AAAGA (3 out of 10 cases, 30%) compared with muta-
tions at other sites in the gene (7 out of 55 cases, 12.7%).
Genotype-phenotype
The clinical characterization of the APC-mutation positive
patients is summarized in Additional file 1 and the char-
acterization of APC- and MUTYH-mutation negative
patients are presented in Table 1. Probands with muta-
tions between codon 1250 and 1468 in the APC gene,
which predict a severe course of the colorectal polyposis
[41] were significantly younger at diagnosis compared
with those with mutations outside this region and seem to
have more colorectal polyps. Despite a lower fraction of
patients with dense polyposis among those with muta-
tions outside codon 1250–1464, CRC at diagnosis
occurred often. High age at diagnosis can probably
explain the relatively high risk of having CRC at diagnosis
in this subgroup of probands. Early detection because of
short patients and delay by doctors may explain the rela-
tively low fraction of patients having CRC at diagnosis
among those where the site of the mutation and clinical
features indicate a more severe phenotype. Overall, the
risk for a proband of having a CRC at diagnosis was lower
than previously reported by Björk et al [33] where 67% of
the probands diagnosed between 1912 and 1996 had
CRC at diagnosis. In this previous study a continued
decrease in CRC morbidity among probands was seen
over time being 48% in the last period studied (1977–
1996). In this current study 84% (27 out of 32) of the
probands were diagnosed with FAP during that period or
later (after 1976). Nine of the 27 (33%) probands had
mRNA expression analysis of family 1 of the Swedish Polyposis Registry Figure 5
mRNA expression analysis of family 1 of the Swedish Polyposis Registry. (A) Diagram of part of the results from the 
TaqMan APC mRNA expression analysis, showing the relative mRNA levels calculated by the standard curve method of two 
affected members of family 1 (A and B) and two control individuals (C and D). (B) Diagrams of cDNA sequences of the above 
indicated patients and controls covering the APC c.5465A > T polymorphism.BMC Medicine 2008, 6:10 http://www.biomedcentral.com/1741-7015/6/10
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CRC at diagnosis, which indicates a continued decrease in
CRC at diagnosis over time. This is in agreement with our
other findings. Except for more rapid detection of symp-
tomatic patients with classical FAP in recent years, a shift
over time of probands being diagnosed with FAP towards
a less-severe phenotype, might explain the decrease in
CRC morbidity.
The phenotype of the patient (C157), carrying the c.70C >
T mutation, is in agreement with the suggested genotype-
phenotype correlation where a milder form of polyposis is
proposed to be caused by mutations in the 5' end of the
gene. A model for the attenuated phenotype in patients
carrying mutations in the first four exons of APC have
been suggested by Heppner Goss et al [42], in which the
internal ATG at codon 184 could be used as an alternative
translation initiation codon in the allele carrying a trun-
cating mutation upstream of this site (Figure 1). Such an
alternative start of translation would supply the cell with
an APC protein of almost full length, thus explaining the
attenuated phenotype. Patient C159, with the most 3'
localized mutation was a case of attenuated FAP (100–
1000 polyps, 46 years of age at diagnosis). In family 1
(reduced expression of APC), patient C152 displayed a
classical FAP phenotype including a large number of pol-
yps, duodenal adenomas, and fundic gland polyps (Addi-
tional file 1).
The APC- and MUTYH-mutation negative patients all dis-
play an attenuated form of disease with a low number of
polyps, comparably high age at diagnosis, and a low fre-
quency of extracolonic manifestations. Whether these
patients really are affected by APC-associated FAP can (of
course) be called into question. However, among attenu-
ated cases of FAP in these study we have found very subtle
mutations such as the mosaic case as well as the c.70C > T
mutation and splice-site mutations. Considering these
facts, at least some of the cases could be caused by muta-
tions in APC resulting in only partially inactivation of the
gene function. Since the main purpose of this study was to
achieve as high mutation-detection rate as possible in
families with colorectal polyposis syndromes, using a
range of different molecular genetic techniques, we have
not yet performed any further analyses of the relatively
few mutation negative cases to determine if they belong to
non-polyposis CRC syndromes.
Large deletions of the APC gene
The fraction of large deletions of all APC mutations iden-
tified in the Swedish patients was 9%, which is higher
than the 5% of large deletions reported in [38]. The rela-
tively large number of gross deletions identified could be
a result of the thorough analysis applied for every patient,
including the use of the MLPA technique. It is noteworthy
that no deletion of APC  exon 4 in patient 3765 was
detected using MLPA although it had been identified and
Pedigree presenting a part of family 1 of the Swedish Polyposis Registry Figure 6
Pedigree presenting a part of family 1 of the Swedish Polyposis Registry. Family members where positive linkage to 
APC has been confirmed are indicated with asterisks.BMC Medicine 2008, 6:10 http://www.biomedcentral.com/1741-7015/6/10
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confirmed by other methods. A still untested possibility is
that exon 4 has been translocated to another chromo-
somal locus and thus generates the positive MLPA result.
A case of APC mosaicism
Screening for mosaic mutations in the three APC- and
MUTYH-negative patients with de novo mutations revealed
the c.2700_2701delTC mutation in patient C107. This
mutation was detected in a very low fraction of the lym-
phocytes and was only detectable using the SSCP/HD
analysis (Figure 2A). Owing to the subtle appearance of
this mutation it could easily have been overlooked.
The phenotype of patient C107 does not fit the generally
accepted genotype-phenotype correlation of AFAP, in
which the disease-causing mutations are situated either in
the 5' or 3' regions or the alternatively spliced part of exon
9 (see the introduction). A speculative reason for the
attenuated phenotype could be that the patient is mosaic
in the epithelial cells of the colon. The parents of patient
C107 of age 73 and 80 years as well as her three children,
age 31–40 years, were free of polyps. No CRC has been
diagnosed on either the maternal or paternal side of the
family. The mutation was not detected in blood samples
from the patient's parents or from her three children. It is
possible that either gonadal or somatic mosaicism exists
in patient C107.
APC mutational mosaicism could be a reason for the quite
large number of de novo or sporadic FAP cases that exist
[23-25,40]. In the family of C107 the mutation has not
been passed on to the offspring of the patient and, thus,
this appears to be a sporadic case, but, generally, the exist-
ence of mosaicism is a risk of error in predictive diagnosis
in FAP/AFAP families [43]. In the initial stages, the molec-
ular screening procedure of FAP/AFAP patients uses
mainly PCR-based methods for analysis of the APC gene
in DNA from isolated blood samples. Therefore, the
chances of detecting pathogenic low-frequency APC
mutations that are present only in a small fraction of the
peripheral blood cells or only in the colon are poor.
Approximately 25% of neurofibromatosis type 2 (NF2)
patients have been shown to be cases of mosaicism [44].
When investigating NF2  mutational mosaicism, the
search for constitutional mutations is preferably carried
out initially in tumor cells. Detected mutations could sub-
sequently be verified in blood leukocyte samples. How-
ever, this approach would not be applicable for FAP
mosaisicm as somatic APC  mutations are frequently
found in tumors.
Splice-site affecting mutations
Two novel germline APC mutations that introduce differ-
ent cryptic splice sites are characterized in this study. Both
mutations result in the aberrant splicing of APC exons 7
and 8 and prematurely truncated APC protein, and both
are defined as pathogenic. The aberrant splicing identified
in patient C496 (c.835-7T > G) is caused by an introduc-
tion of a new active splice site 6 bp upstream of the
wildtype AG splice site of intron 7. This acceptor site is
apparently preferred by the splicing machinery, as shown
by the results of the cDNA sequencing (Figure 3). The
c.834G > C substitution at the last nucleotide of exon 7 in
patient C633, would theoretically introduce a missense
mutation at codon 278. However, as demonstrated by the
cDNA sequencing results (Figure 4) the mutation leads to
the use of a cryptic splice donor site 11 bp upstream in
exon 7. This real outcome of the mutation would easily
have been overlooked unless the RNA-based methods had
been used. Other examples of aberrant splicing of the APC
gene due to missense mutations have recently been
described [16]. One case of use of aberrant splice-acceptor
site of APC  exon 8 has been reported previously in a
patient with classical polyposis [15]. However, an alterna-
tive acceptor splice site (c.845-17A > G) in intron 7 has
been reported from a patient with a milder phenotype,
multiple synchronous colorectal adenomas [45].
Owing to the fact that RNA-based PTT was used at the ini-
tial stage of the mutational screening, detection of the dis-
ease-causing splice-site mutations was straightforward.
Sequencing of genomic DNA was then used to pinpoint
the genetic alteration causing the aberrant mRNA
sequence that was visualized in the PTT experiments. The
use of both DNA- and mRNA-based methods is a prereq-
uisite for high-quality investigation of splice-site muta-
tions.
A case of reduced APC expression
The study of mRNA levels was the next step in the line of
investigation of the cause of disease in patients with no
detected APC mutation. Family 1 is the largest kindred in
the Swedish Polyposis Registry; this family includes 150
individuals of whom 57 are affected by the disease (Figure
6 shows part of the pedigree). However, no pathogenic
mutation had been detected after screening the whole
coding region of the APC gene but as the family did show
positive linkage to the APC locus we decided to perform
expression analyses and evidence of lowered APC expres-
sion was obtained by quantitative real-time PCR (Figure
5A). The result was supported by the indication of a lower
expression from the T-allele from analysis of the APC
c.5465A > T polymorphism in the cDNA sequencing dia-
gram of two affected family members (Figure 5B). The
search for mutations in the DNA sequence of the APC pro-
moters has been initiated, but no pathogenic change has
been detected to this date. The possibility of the patho-
genic change being epigenetic will have to be investigated
further. Hypermethylation of CpG sites in the promoter of
APC has been reported as a means of gene silencing inBMC Medicine 2008, 6:10 http://www.biomedcentral.com/1741-7015/6/10
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colorectal tumors [46-49]. To the best of the authors'
knowledge no germ-line inactivation of APC caused by
promoter hypermethylation has been reported. However,
cases of pathogenic germline epimutations have been
identified in the MLH1  gene, which causes hereditary
non-polyposis CRC [50,51].
Mutation-detection frequency
The 61 different APC mutations listed in Additional file 2
were identified among 81 of the 96 families of the Swed-
ish Polyposis Registry that were screened for APC muta-
tions. Fifteen of the cases shown to be APC-mutation
negative where all subjected to mutational screening of
the MUTYH gene and six of them were shown to carry
biallelic MUTYH mutations (reported in Kanter Smoler et
al[31]). The overall mutation-detection rate in APC and
MUTYH among the families in our study was thus 90%.
In total, 84% of the families carried APC mutations while
6% where positive for biallelic MUTYH mutations. The
mutation-detection rate we have reached in this study is
notably high. In fact, a disease-causing mutation was
detected in all cases who presented with a classical FAP
phenotype (except for family 1 (C152), where we have
clear indications for inactivation of the APC  transcrip-
tion). The mutation-negative patients all display an atten-
uated form of disease. However, as we have also found
subtle mutations in the APC gene in patients with attenu-
ated FAP, we have to consider inactivation of APC to be
responsible for some of these FAP cases.
Conclusion
We want to emphasize the importance of using a combi-
nation of techniques to achieve the highest mutation-
detection frequency possible and it is also noteworthy
that RNA-based screening is of importance when conduct-
ing a highly sensitive mutation-detection screening pro-
gram as a number of mutations might otherwise be
overlooked. The use of mRNA analyses has been crucial in
order to detect and characterize splice variants and also to
complement MLPA analyses. The MLPA method has
improved and simplified the screening procedure signifi-
cantly, but it is important to remember the limits of the
method, which in our study is exemplified by a possible
translocation that is not detectable by MLPA. Further-
more, the need to detect elusive APC  changes such as
mosaicism, which are not easily identified using standard
techniques, remains. Such APC  mutations may be the
cause of some of the so-far unresolved de novo cases of
attenuated or atypical FAP. Clinical data from this study
indicate that the risk of having CRC at diagnosis among
probands with mutations outside the region codon 1250–
1464, although exhibiting a less-severe phenotype, is high
indicating that age at diagnosis rather than severity of the
disease predicts CRC morbidity. Early detection of
probands contributes to the decrease in overall CRC mor-
bidity seen in FAP in recent years.
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